Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$2.5 billion.

  • Intellia Therapeutics' Retained Earnings fell 2176.25% to -$2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 billion, marking a year-over-year decrease of 2176.25%. This contributed to the annual value of -$2.2 billion for FY2024, which is 3129.69% down from last year.
  • As of Q3 2025, Intellia Therapeutics' Retained Earnings stood at -$2.5 billion, which was down 2176.25% from -$2.4 billion recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Retained Earnings high stood at -$481.3 million for Q1 2021, and its period low was -$2.5 billion during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$1.4 billion (2023), whereas its average is -$1.4 billion.
  • Per our database at Business Quant, Intellia Therapeutics' Retained Earnings tumbled by 7657.35% in 2022 and then crashed by 2176.25% in 2025.
  • Intellia Therapeutics' Retained Earnings (Quarter) stood at -$703.0 million in 2021, then tumbled by 67.45% to -$1.2 billion in 2022, then crashed by 40.88% to -$1.7 billion in 2023, then tumbled by 31.3% to -$2.2 billion in 2024, then fell by 14.55% to -$2.5 billion in 2025.
  • Its Retained Earnings stands at -$2.5 billion for Q3 2025, versus -$2.4 billion for Q2 2025 and -$2.3 billion for Q1 2025.